---
figid: PMC11012347__ijms-25-04096-g003
figtitle: 'Integrin in Cardiovascular Diseases: From Basic Research to Clinical Implications'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11012347
filename: ijms-25-04096-g003.jpg
figlink: /pmc/articles/PMC11012347/figure/ijms-25-04096-f003/
number: F3
caption: 'A summary diagram of integrin-based cardiovascular disease treatment methods
  and therapeutic drugs. (A) The use of integrin antagonists to block the binding
  of integrins with ligands, thereby inhibiting signal pathway transmission and CVD
  progression. (B) The use of NPs to enhance targeting specificity and bioavailability,
  delay drug release, and mitigate drug toxicity in the treatment of CVDs. Abbreviations:
  CVD: cardiovascular disease, VEC: vascular endothelial cell, VSMC: vascular smooth
  muscle cell, VEGF: vascular endothelial growth factor, NP: nanoparticle, RGD-peptide:
  arginine–glycine–aspartate peptide, RAP: rapamycin, cRGDfK peptide: cyclic arginyl–glycyl–aspartic
  acid–phenylalanine–lysine peptide, PLGA-Pep-PEG: poly (lactic-co-glycolic acid)–peptide–polyethylene
  glycol, RGDfC: Arg-Gly-Asp-Phe-Cys, RAP@T/R NPs: RAP targeted and responsive nanoparticles.'
papertitle: 'Roles of Integrin in Cardiovascular Diseases: From Basic Research to
  Clinical Implications.'
reftext: Shuo Zhang, et al. Int J Mol Sci. 2024 Apr;25(7):4096.
year: '2024'
doi: 10.3390/ijms25074096
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: integrins | cardiovascular diseases | vascular endothelial cells | vascular
  smooth muscle cells | platelets | cardiac fibroblasts | cardiomyocytes | integrin
  antagonists and antibodies | nanotherapy
automl_pathway: 0.8869533
figid_alias: PMC11012347__F3
figtype: Figure
redirect_from: /figures/PMC11012347__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11012347__ijms-25-04096-g003.html
  '@type': Dataset
  description: 'A summary diagram of integrin-based cardiovascular disease treatment
    methods and therapeutic drugs. (A) The use of integrin antagonists to block the
    binding of integrins with ligands, thereby inhibiting signal pathway transmission
    and CVD progression. (B) The use of NPs to enhance targeting specificity and bioavailability,
    delay drug release, and mitigate drug toxicity in the treatment of CVDs. Abbreviations:
    CVD: cardiovascular disease, VEC: vascular endothelial cell, VSMC: vascular smooth
    muscle cell, VEGF: vascular endothelial growth factor, NP: nanoparticle, RGD-peptide:
    arginine–glycine–aspartate peptide, RAP: rapamycin, cRGDfK peptide: cyclic arginyl–glycyl–aspartic
    acid–phenylalanine–lysine peptide, PLGA-Pep-PEG: poly (lactic-co-glycolic acid)–peptide–polyethylene
    glycol, RGDfC: Arg-Gly-Asp-Phe-Cys, RAP@T/R NPs: RAP targeted and responsive nanoparticles.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FGA
  - FGB
  - FGG
  - IGKV2-26
  - EEF1B2P2
  - BHLHE22
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - SERPINA4
  - NPS
  - RNPC3
  - LRPAP1
  - Eptifibatide
  - Tirofiban
  - Fibrin
  - Antagonists
---
